Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Seragon Pharmaceuticals

http://www.seragonpharm.com/

Latest From Seragon Pharmaceuticals

ASCO Data Position Contenders In Battle Of The SERDs

With at least two potential candidates being touted as potential best-in-class by their sponsors, the oral SERD market is shaping up to be highly competitive. Sanofi has taken an early lead in expanding the scope of its Phase III breast cancer program.

ASCO Clinical Trials

Roche Pharma Chief Picks Out Pearls in Cancer Pipeline

Oncology is an area where the Swiss major has long been a dominant player, and Bill Anderson highlighted programs to Scrip which Roche hopes will help extend that dominance.

Cancer Clinical Trials

Venture Funding Deals: Celularity Launches With $250m; Generation Bio Grabs $100m Series B

Celularity launched with $250m to develop cell therapies with technology licensed from Celgene and others, while mRNA specialist Moderna brought in another $500m mega round and Generation Bio closed a $100m Series B to fund ongoing gene therapy programs.

Financing StartUps and SMEs

J&J’s Stoffels On Actelion’s ‘Exquisite’ Researchers, India TB R&D Plans

J&J’s chief scientific officer Dr. Paul Stoffels tells Scrip that flexibility is a hallmark of how the company goes about its collaborations, including the new $30bn deal with Actelion. Stoffels is also hoping to progress the science for a new TB medicine via a unique collaboration in India.

Commercial Strategy
See All

Company Information

UsernamePublicRestriction

Register